ScholarIQanswers from OpenAlex
Rocky Mountain MS Center
InstitutionResearch output, impact & collaborations
Rocky Mountain MS Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Rocky Mountain MS Center?
ScholarIQrecord summary
Rocky Mountain MS Center is a research organisation in Englewood, US. OpenAlex records 2,224 works and 120,267 citations for it. 423 researchers list it as their most recent affiliation.
How many works does Rocky Mountain MS Center have?
ScholarIQindexed works
Rocky Mountain MS Center has 2,224 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Rocky Mountain MS Center have?
ScholarIQcitation count
Rocky Mountain MS Center has 120,267 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Rocky Mountain MS Center?
ScholarIQresearcher count
Rocky Mountain MS Center has 423 researchers in the ScholarIQ index.
What is the average h-index at Rocky Mountain MS Center?
ScholarIQavg h-index
Rocky Mountain MS Center has an average h-index of 35.5 in OpenAlex.
What is the ROR of Rocky Mountain MS Center?
ScholarIQror
The ROR for Rocky Mountain MS Center is on the source record.
What is the OpenAlex record for Rocky Mountain MS Center?
ScholarIQopenalex
The OpenAlex for Rocky Mountain MS Center is on the source record.
Who are the most-cited researchers behind Rocky Mountain MS Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Rocky Mountain MS Center?
ScholarIQmost cited works
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Jay M. Edelberg, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Guillaume Lecorps, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Kirby Quintero, Matthew T. Roe, William J. Sasiela, Jean‐François Tamby, Pierluigi Tricoci, Harvey D. White, Andreas M. Zeiher
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz, Anders Olsson, Markus Abt, Christie M. Ballantyne, Philip J. Barter, Jochen Brumm, Bernard Chaitman, Ingar Holme, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, John J.V. McMurray, Hardi Mundl, Stephen J. Nicholls, Prediman K. Shah, Jean‐Claude Tardif, R. Scott Wright
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Walter N. Kernan, Catherine M. Viscoli, Karen L. Furie, Lawrence H. Young, Silvio E. Inzucchi, Mark Gorman, Peter Guarino, Anne M. Lovejoy, Peter Peduzzi, Robin Conwit, Lawrence Brass, Gregory G. Schwartz, Harold P. Adams, Léo Berger, Antonio Carolei, Wayne M. Clark, Bruce M. Coull, Gary A. Ford, Dawn Kleindorfer, John R. O’Leary, Mark Parsons, Peter A. Ringleb, Souvik Sen, J. David Spence, David Tanné, David Wang, Toni R. Winder
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Matthew T. Roe, Tyrus Rorick, William J. Sasiela, Cheerag Shirodaria, Michael Szarek, Jean‐François Tamby, Pierluigi Tricoci, Harvey D. White, Andreas M. Zeiher, Philippe Gabríel Steg
Regional gray matter volumetric changes in autism associated with social and repetitive behavior symptoms
Donald C. Rojas, Eric Peterson, Erin Winterrowd, Martin Reite, Sally J. Rogers, Jason R. Tregellas
How much of the research on Rocky Mountain MS Center is open access?
ScholarIQopen access share
75%OPEN ACCESS